title: Human PXR-mediated induction of intestinal CYP3A4 attenuates 1α,25-dihydroxyvitamin D₃ function in human colon adenocarcinoma LS180 cells.
abstract: Oxidative catabolism of 1α,25-dihydroxyvitamin D(3) [1α,25(OH)(2)D(3)] is mediated by either CYP24A1 or CYP3A4. In this paper, we tested whether induction of CYP3A4 in the LS180 intestinal cell model enhances clearance of 1α,25(OH)(2)D(3) and blunts its hormonal effect on expression of the apical membrane calcium transport protein, TRPV6. Treatment with the hPXR agonist rifampin significantly increased CYP3A4 mRNA content and catalytic activity, but had no effect on CYP24A1 or TRPV6 mRNA content. Pre-treating cells with rifampin for 48h, prior to a 24h 1α,25(OH)(2)D(3) treatment phase, was associated with a subsequent 48% increase in the elimination of 1α,25(OH)(2)D(3) and a 35% reduction of peak TRPV6 mRNA. Introduction of the CYP3A4 inhibitor, 6',7'-dihydroxybergamottin, an active inhibitor in grapefruit juice, reversed the effects of rifampin on 1α,25(OH)(2)D(3) clearance and TRPV6 expression. Over-expression of hPXR in LS180 cells greatly enhanced the CYP3A4 responsiveness to rifampin pretreatment, and elicited a greater relative suppression of TRPV6 expression and an increase in 1α,25(OH)(2)D(3) disappearance rate, compared to vector expressed cells, following hormone administration. Together, these results suggest that induction of CYP3A4 in the intestinal epithelium by hPXR agonists can result in a greater metabolic clearance of 1α,25(OH)(2)D(3) and reduced effects of the hormone on the intestinal calcium absorption, which may contribute to an increased risk of drug-induced osteomalacia/osteoporosis in patients receiving chronic therapy with potent hPXR agonists. Moreover, ingestion of grapefruit juice in the at-risk patients could potentially prevent this adverse drug effect.
authors.affiliation: Department of Pharmaceutics, University of Washington, Seattle, WA 98195-7610, United States.
authors.forename: Xi Emily
authors.initials: XE
authors.lastname: Zheng
authors.forename: Zhican
authors.initials: Z
authors.lastname: Wang
authors.forename: Michael Z
authors.initials: MZ
authors.lastname: Liao
authors.forename: Yvonne S
authors.initials: YS
authors.lastname: Lin
authors.forename: Margaret C
authors.initials: MC
authors.lastname: Shuhart
authors.forename: Erin G
authors.initials: EG
authors.lastname: Schuetz
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Thummel
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology*; D018938:Caco-2 Cells; D002118:Calcium / Q000378:metabolism; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000201:enzymology*; D051544:Cytochrome P-450 CYP3A / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D004790:Enzyme Induction / Q000187:drug effects / Q000502:physiology; D006801:Humans; D000077297:Pregnane X Receptor; D011987:Receptors, Steroid / Q000819:agonists / Q000502:physiology*; D012293:Rifampin / Q000494:pharmacology*; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D000077297:Pregnane X Receptor; D011987:Receptors, Steroid; C118756:dihydroxy-vitamin D3; D014807:Vitamin D; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D002118:Calcium; D012293:Rifampin